GLP-1 Receptor Agonists

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Indications

Primary Indications

Type 2 Diabetes (approved)Obesity/Weight Management (approved)Major Depressive Disorder (investigational)Treatment-Resistant Depression (investigational)Anhedonia (investigational)Substance Use Disorders — alcohol, nicotine, stimulants (investigational)Neurodegenerative and cognitive disorders (exploratory)

Mechanism

GLP-1 receptor agonists act centrally and peripherally. Centrally, they are believed to attenuate mesolimbic dopamine signaling related to cue-reactivity and craving, reduce neuroinflammation (microglial activation), and support neuroplasticity in cortico-striatal-limbic circuits. Peripherally, they improve insulin sensitivity and weight, which may indirectly benefit mood and cognition.

Protocol

Preparation

Baseline metabolic panel, HbA1c, weight/BMI, and psychiatric assessment if used in trials.

Procedure

Administer per diabetes/obesity labeling (weekly subcutaneous semaglutide, daily oral semaglutide, or daily liraglutide) within research protocols for psychiatric indications.
Combine with psychotherapy or standard-of-care treatments for depression or SUDs where applicable.
Track craving, substance use days, and mood scales at regular intervals.

Frequency: Daily or weekly dosing depending on agent and formulation.

Duration: Weeks to months; durability of psychiatric effect under investigation.

Total Treatment Time: Protocol-dependent; often ≥12 weeks in trials.

Expected Outcomes

Immediate

Early GI effects (nausea, decreased appetite)

Short Term

Weight loss/metabolic improvement; potential reductions in craving and improved mood in responders

Long Term

Sustained metabolic benefit; possible continued mood and craving improvements with adherence

Side Effects

common

Nausea
Vomiting
Diarrhea
Constipation
Decreased appetite

uncommon

Gallbladder disease
Injection-site reactions
Dehydration

rare

Pancreatitis
Acute kidney injury (secondary to dehydration)

Warnings

Critical Safety Information

→Boxed warning for thyroid C-cell tumors in rodents (human relevance uncertain).
→Use caution in patients with history of pancreatitis.
→Slow dose titration helps mitigate GI adverse effects.

Monitoring

Weight, BMI, waist circumference
HbA1c, fasting glucose, lipids
GI symptoms and hydration status
Mood (e.g., PHQ-9) and craving/relapse metrics in SUD trials

Special Populations

👶Pregnancy

Not recommended; weight loss is not indicated during pregnancy.

🤱Breastfeeding

Unknown excretion in human milk; weigh risks/benefits.

👧Children & Adolescents (Under 18)

Semaglutide approved for adolescent obesity; psychiatric use not established.

👴Older Adults (65+)

Generally tolerable; monitor renal function and GI tolerance.

Clinical Notes

Rationale for SUDs: modulation of mesolimbic reward and cue-reactivity may reduce craving and consumption.
Particularly promising for patients with comorbid obesity/metabolic syndrome and depression or SUDs.
Psychiatric indications remain investigational; prioritize use within controlled research or with careful documentation.

This treatment information is for educational purposes only. Treatment decisions should be made in consultation with qualified healthcare professionals based on individual circumstances, symptoms, and medical history. Do not attempt treatment without professional guidance.

Interested in this treatment?

This information is for educational purposes. Always consult with a qualified healthcare provider before starting any new treatment.

Locate Psychiatrists